Mahana Therapeutics Plans To Use $61M In Series B Financing To Launch IBS Treatment App
Executive Summary
Mahana is planning a 2022 nationwide launch of its FDA-cleared prescription digital therapeutic for treating symptoms of irritable bowel syndrome.
You may also be interested in...
Bayer CH Backs Digital Therapeutics With ‘Multimillion-Dollar’ Mahana Partnership
A multimillion-dollar partnership will bring together Bayer Consumer Health's digestive health brand equity with Mahana's cutting edge digital therapeutic technology for treating irritable bowel syndrome.
Gut-Brain Connect: metaMe’s Digital Therapeutic Hopes To Rewire IBS Treatment
metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia explained their plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.
Gut-Brain Connect: How metaMe’s Digital Therapeutic Hopes To Rewire IBS Treatment
metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia discuss with Scrip plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.